Fecal Microbiota Transplantation (FMT): Principle, Procedure, Uses, and Risks

The idea sounds startling the first time you hear it: to cure a gut infection, transfer stool from a healthy person into a sick person's intestine. Yet fecal microbiota transplantation is one of the most effective treatments in modern medicine for a specific, difficult problem, recurrent Clostridioides difficile infection, and understanding why it works is one of the clearest lessons in what the gut microbiome actually does. This page explains the principle behind FMT, how it is carried out, what it is used for, and its risks.

What is fecal microbiota transplantation?

Fecal microbiota transplantation (FMT), also called fecal bacteriotherapy or intestinal microbiota transplantation, is the transfer of processed stool from a carefully screened healthy donor into the gut of a patient, in order to restore a healthy, diverse community of gut bacteria.

Its main established use is recurrent Clostridioides difficile infection (rCDI), the infection that keeps coming back after antibiotic treatment. This is not a coincidence: C. difficile infection is fundamentally a disease of a disrupted microbiome (antibiotics wipe out the normal gut flora, letting C. difficile overgrow), so restoring that flora directly attacks the root of the problem in a way antibiotics cannot.

The principle: why FMT works

The logic follows directly from what goes wrong in C. difficile infection.

A healthy colon contains hundreds of species of bacteria that compete for space and nutrients and keep any single organism from taking over. This crowding-out effect is called colonization resistance, and it is what normally keeps C. difficile in check. Broad-spectrum antibiotics destroy much of this community, removing the competition and allowing C. difficile spores to germinate and overgrow. Treating with yet more antibiotics can clear the organism temporarily, but it also keeps the normal flora suppressed, which is why the infection so often returns.

FMT breaks this cycle. By introducing a complete, diverse microbial community from a healthy donor, it re-establishes colonization resistance: the transplanted bacteria repopulate the colon, out-compete C. difficile, and restore the normal balance. This is why FMT succeeds where repeated antibiotic courses fail, and why it is one of the clearest demonstrations that the gut microbiome is a functioning organ, not just passive flora.

How fecal transplantation is done

FMT has three stages: selecting and screening a donor, preparing the material, and delivering it.

Donor selection and screening. The donor may be a related or unrelated healthy person, or, increasingly, an anonymous donor supplying a regulated stool bank. Rigorous screening is the single most important safety step (see Risks below): donors are questioned about risk factors and their blood and stool are tested for a broad panel of transmissible agents, including bacterial pathogens, multidrug-resistant organisms, viruses, and parasites. Stool that passes screening is often quarantined until repeat testing confirms the donor remains negative.

Preparation. Donor stool is mixed with saline (or another diluent), filtered to remove solid material, and processed into a suspension. Depending on the delivery route, it may be used as a liquid or further processed, and modern products are frozen and stored until use.

Delivery. The prepared microbiota can be introduced by several routes, and the choice depends on the clinical situation and what is available:

• Colonoscopy: delivering the suspension directly into the colon. This is commonly used and allows inspection of the bowel at the same time.
• Nasoenteric tube: a tube passed through the nose into the stomach or small intestine (upper delivery).
• Enema: instilling the suspension into the lower colon.
• Oral capsules: swallowable capsules containing processed or freeze-dried microbiota. This is the least invasive route and the basis of newer products.

No single route is best for everyone; capsules and enemas are simpler, while colonoscopy allows direct placement and visualization.

Approved products and the modern picture

For most of FMT's history it was performed as an unstandardized, "do-it-yourself" procedure using freshly prepared donor stool, which made safety and quality hard to control. That has changed. Standardized, quality-controlled microbiota products are now approved by the US FDA for preventing recurrence of C. difficile infection in adults after antibiotic treatment:

• Rebyota (fecal microbiota, live-jslm), approved in November 2022, the first FDA-approved fecal microbiota product. It is a single-dose suspension given as a rectal enema, prepared from screened donor stool.
• Vowst (fecal microbiota spores, live-brpk), approved in April 2023, the first orally administered fecal microbiota product, taken as capsules over several days.

Both are indicated to prevent recurrence of CDI in adults following antibiotic treatment for recurrent infection, not as a first treatment. Their arrival marks FMT's shift from an improvised procedure to a regulated therapy with defined donor screening and manufacturing standards.

Uses of FMT

Established: recurrent C. difficile infection is the one clear, evidence-based indication, with high success rates (often reported above 80 to 90 percent) in patients who have relapsed after standard antibiotic therapy. Major guidelines recommend FMT for multiply-recurrent CDI.

Investigational: FMT is being studied in a range of other conditions linked to the gut microbiome, including inflammatory bowel disease (ulcerative colitis), irritable bowel syndrome, and metabolic and other disorders. These uses are not yet established, results are mixed, and FMT should be regarded as experimental outside recurrent CDI. It is honest to say the science here is still developing.

Risks of FMT

FMT is generally well tolerated, and serious events are uncommon, but the risks are real and they center on one thing: you are transferring living microorganisms from one person to another.

Transmission of pathogens is the central risk. Even with careful screening, a donor may carry an organism the screening did not detect. This is not theoretical. In June 2019 the FDA issued a safety alert after two immunocompromised patients developed invasive infections with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli transmitted through FMT from the same donor; one of the patients died. The donor stool had not been tested for ESBL-producing organisms. In response, the FDA required enhanced donor screening and testing for multidrug-resistant organisms, and further alerts followed (including transmission of other pathogenic E. coli in 2020). These events are the direct reason donor screening is now so rigorous, and they are why unscreened, informal "do-it-yourself" FMT is dangerous.

Procedural risks depend on the delivery route: colonoscopy and nasoenteric tubes carry their own small risks (for example, bowel perforation or aspiration), and any route can cause transient bloating, cramping, or diarrhea.

Immunocompromised patients are at higher risk from any transmitted organism, which is why the balance of benefit and risk must be weighed especially carefully in them.

How to remember

Restore the garden, don't just pull the weed. Antibiotics pull the weed (C. difficile) but leave the soil bare, so the weed grows back. FMT replants the whole garden (the normal flora), which then crowds the weed out. That is colonization resistance restored.

FMT treats the recurrence, not the first attack. Its established use is recurrent CDI, after standard antibiotics have failed, not first-line therapy.

The whole risk is in the donor. FMT transfers living microbes, so a missed pathogen in the donor is the key danger. The 2019 FDA alert (a fatal ESBL E. coli transmission) is why donor screening is now strict, and why informal DIY FMT is unsafe.

Key exam facts

Where students get confused

FMT is not a first-line treatment for C. difficile. It is used for recurrent infection after standard antibiotics have failed. First-episode CDI is treated with antibiotics (oral vancomycin or fidaxomicin).

It works by restoring flora, not by killing the organism. FMT contains no antibiotic. It cures by re-establishing the normal microbial community that out-competes C. difficile. This is the opposite logic to antibiotic treatment.

"Approved products" and "traditional FMT" are not the same thing. Rebyota and Vowst are standardized, quality-controlled, FDA-approved products. Traditional FMT using freshly prepared donor stool is a procedure, not a licensed product, and its quality and safety depend entirely on the screening and preparation done locally.

The risk lives in the donor, and screening is what manages it. The efficacy of FMT can make it sound risk-free, but transferring living microbes means an unscreened donor can transmit a lethal pathogen, as the 2019 FDA alert showed. Screening is not a formality; it is the safety mechanism.

References

1. U.S. Food and Drug Administration. Safety alert: risk of serious adverse events likely due to transmission of multi-drug resistant organisms with fecal microbiota for transplantation. June 13, 2019. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/
2. Ferring Pharmaceuticals. FDA approval of REBYOTA (fecal microbiota, live-jslm). November 30, 2022.
3. U.S. Food and Drug Administration. FDA approves first orally administered fecal microbiota product (VOWST). April 2023.
4. McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by IDSA and SHEA. Clin Infect Dis. 2018;66(7):e1-e48. https://doi.org/10.1093/cid/cix1085
5. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569-580. https://doi.org/10.1136/gutjnl-2016-313017